Pediatric clinical trial consent: essential preparation steps

The dual-framework structure of pediatric research consent confuses even seasoned clinicians, and the confusion has consequences. A trial can have its protocol approved, its IRB sign-off in hand, and its investigators ready to enroll — and still collapse at the consent station when a family does not understand the difference between parental permission and child assent. I've watched enrollment stalling events where the document was technically complete but the discussion behind it was never held. This checklist exists because consent in pediatric trials is not a signature line; it is a process with regulatory teeth, and the preparation needs to start long before anyone picks up a pen.

The Dual-Framework: Distinguishing Parental Permission from Child Assent

The first thing I tell every site coordinator I train is this: parents do not give informed consent for their child. They give permission. The child, when capable, gives assent. These are legally distinct acts under the US Common Rule, and conflating them is one of the cleanest ways to generate a finding from an FDA inspector or an OHRP compliance letter.

Under 45 CFR 46 Subpart D and FDA 21 CFR 50 Subpart D, parental permission is the legally binding authorization that allows a minor to be enrolled in a clinical investigation. Assent, defined under 45 CFR § 46.402(b), is the child's affirmative agreement to participate — a positive act, not passive non-objection. A child who sits quietly through the consent discussion and never says no has not assented. Silence is not agreement in this regulatory framework.

Permission and assent are not the same document, and treating them as one is a compliance failure waiting for an audit.

In my experience running these cohorts, the site teams that get this distinction right are the ones who build two conversations into the consent visit — one with the parent, one with the child — rather than reading the entire form aloud to the family as a single unit. The format matters less than the structure.

Regulatory Foundations: Navigating 45 CFR 46 and FDA Subpart D Protections

The pediatric research landscape is governed by overlapping federal frameworks, and the overlap is intentional. HHS 45 CFR 46 Subpart D establishes the baseline protections for children as research subjects, layering additional safeguards on top of the general Common Rule. FDA 21 CFR 50 Subpart D does the same for clinical investigations involving FDA-regulated products, including investigational drugs, biologics, and devices. When a trial falls under both — and most pediatric IND studies do — both sets of provisions apply simultaneously.

Subpart D classifies pediatric research into four categories based on risk and potential benefit: research not involving greater than minimal risk, research involving greater than minimal risk with prospect of direct benefit, research involving greater than minimal risk with no prospect of direct benefit but likely to yield generalizable knowledge, and research not otherwise approvable that presents an opportunity to understand a serious condition. Each tier triggers different consent and permission requirements, and the IRB is responsible for assigning the category at the protocol review stage.

Parents should ask which category their child's study falls into. The answer determines whether permission alone is sufficient, whether both permission and assent are required, and whether additional safeguards — like a data and safety monitoring board — must be in place. I have seen parents sign a permission form without ever learning that the IRB had classified the study at the third or fourth tier. That is a breakdown in informed participation, even if every signature is technically correct.

The HHS Informed Consent Checklist, issued in 1998 and updated since, lays out the essential elements that any consent document must contain: a statement that the study involves research, an explanation of its purpose, the expected duration, a description of procedures, identification of any experimental procedures, a reasonable risk disclosure, a benefit disclosure, alternatives to participation, confidentiality protections, compensation arrangements for injury, contact information, and a clear statement that participation is voluntary. None of these elements is optional, and the order in which they appear is not arbitrary — regulatory inspectors read these documents in sequence, looking for gaps.

Assessing Cognitive Maturity: How IRBs Determine the Capacity for Assent

One of the most persistent misconceptions I encounter is the assumption that there is a universal age at which children must be asked to sign an assent form. There is not. Federal regulations under both HHS and FDA deliberately leave the determination of assent capability to the IRB, which evaluates each protocol — and often each potential subject — against age, maturity, and psychological state.

What this means practically is that a seven-year-old in one trial may be deemed capable of providing meaningful verbal assent, while a twelve-year-old in another trial, depending on the condition being studied and the cognitive demands of the protocol, may not. The IRB factors in the complexity of the decision, the child's developmental stage, the severity of their illness, and whether the protocol requires sustained cooperation that the child can genuinely comprehend.

For families, the practical implication is straightforward: ask the study team what format the assent takes in this particular protocol. Some IRBs require a separate written assent document for children above a certain maturity threshold. Others use a simplified verbal assent script read aloud and documented in the research record. A few waive the assent requirement entirely, in writing, when the children are too young or too ill to participate meaningfully in the decision. Each approach is defensible under federal regulations — what is not defensible is assuming the form will be obvious when you arrive.

Questions to ask the study team about assent

1. What format does the IRB-approved assent take for this protocol — written, verbal, or waived?

2. How will the team assess my child's understanding before asking for their agreement?

3. If my child declines to assent, does the protocol permit override by parental permission alone?

4. Will the assent be revisited at any point during the study, or only at enrollment?

5. Is there an age or maturity cutoff specified in the IRB-approved plan, and what does it look like in practice?

The third question matters more than most parents realize. There are limited circumstances under which an IRB can waive the assent requirement — for example, when the research offers a direct therapeutic benefit not available outside the study and the intervention is consistent with standard care. Outside those narrow categories, a child who actively declines is not a research subject, regardless of what the parent has signed.

The Transition to Adulthood: Re-consent Requirements Under EU CTR Article 32

For trials conducted in the European Union, or for multinational trials that include EU member states, the consent process does not necessarily end at enrollment. Under EU Clinical Trials Regulation 536/2014, Article 32 specifically addresses what happens when a minor participant reaches the age of legal competence during an ongoing study. The age threshold is not uniform — it is set by each member state's national law, typically 16 or 18 years depending on the jurisdiction.

What Article 32 requires is re-consent: the now-adult participant must provide their own informed consent to continue in the study. This is not a formality. The participant who enrolled as a six-year-old and turns eighteen mid-trial must independently agree to continued participation, with all the disclosure requirements that adult informed consent entails. If they decline, their data collected up to that point may still be used depending on the protocol and applicable national provisions, but no further study procedures may occur.

The UK handles this differently in some respects. Under the Medicines for Human Use (Clinical Trials) Regulations, children under 16 cannot give legal consent to participate in a Clinical Trial of an Investigational Medicinal Product (CTIMP). Consent must come from a parent or legal representative. When the participant turns 16, however, the regulatory expectation under updated NHS Health Research Authority guidance is that the young person is re-consented in a manner appropriate to their now-legal status.

Re-consent is not a renewal — it is a fresh decision by a person who did not exist legally when the study began.

For parents preparing for a long-duration pediatric trial — gene therapy follow-up cohorts, for instance, that track participants for fifteen years — this re-consent milestone should be part of the conversation at enrollment, not a surprise at year twelve. I have reviewed protocols where the re-consent process was not operationalized until the first participant aged out, and the scramble was avoidable.

Essential Documentation: Preparing for the Informed Consent Discussion

The consent document itself is the artifact, but the discussion around it is the consent. A well-prepared family does not need to read the entire document in the clinic; they need to know what to look for, what to ask, and what their rights look like in practice.

Here is what I tell every parent who asks me how to prepare:

• Read the protocol summary before the visit, not after. The IRB-approved summary is the section that distills the study into plain-language essentials. If your site does not offer one in advance, request it.
• Bring a second adult. Two sets of ears catch different things, and the consent visit is too information-dense to rely on a single listener.
• Ask about the safety reporting plan. How will adverse events be communicated to you, on what timeline, and through what channel? This is not in the consent form by default — it is in the protocol.
• Clarify the data handling. Where will biological samples be stored, for how long, and can you withdraw them? Pediatric trials frequently include optional substudies on stored samples, and these are separate consent decisions.
• Confirm the compensation structure. Not whether payment exists, but what it covers — travel, time, procedure-related discomfort, lost wages for caregivers. The line items matter.
• Request the IRB contact information. Every consent document includes it; few parents note it. If something during the study feels wrong, this is the channel.

For site teams, the corresponding checklist is shorter but stricter:

1. Confirm both parental permission and, where applicable, child assent documents are present, current, and IRB-approved.

2. Verify the regulatory basis for each consent element — 45 CFR 46.116 for adults, Subpart D for pediatric provisions.

3. Document the assent process separately from the permission process, even when both occur in the same visit.

4. For multi-jurisdictional studies, confirm whether EU CTR Article 32 re-consent applies and at what age.

5. Reconfirm the IRB's risk classification of the study and that the consent reflects it accurately.

What Actually Gets Missed

In my audits of consent processes — both internal and as part of due diligence for sponsors acquiring trial data — the most common failure is not a missing signature. It is an absent conversation. The forms are complete, the dates are correct, the witness line is filled in, and the family leaves with no real understanding of what they agreed to.

This happens when consent is treated as a transaction rather than a process. The investigator reads the form, the parent signs, the child is enrolled. The regulatory requirements are met on paper. But the spirit of Subpart D — that children deserve protections beyond what adult research requires because they cannot fully advocate for themselves — is hollow if the conversation that informs their participation never happens.

A signed form is evidence of a discussion, not a substitute for one.

For parents, the practical test is simple: after the consent visit, can you describe the primary endpoint, the known adverse events, the alternative to participation, and the circumstances under which your child's data could be shared? If not, the consent process failed, and you are within your rights to ask for another session before signing.

For investigators and sponsors, the same test applies in reverse: can you document that the family understood those four points before the form was signed? The FDA's expectation, reinforced through 21 CFR 50 Subpart D, is that consent is a process of disclosure and comprehension, not a moment of signature. When that process is rushed, the regulatory exposure is real, but the human cost is higher — families who enroll without understanding what they have agreed to, and children whose participation was never meaningfully informed.

The dual-framework structure of pediatric consent exists because children are not small adults and parents are not sole decision-makers. Both voices matter. Preparation is what makes both audible.